Rapid and Deep Response to Lorlatinib in Pancreatic High-Grade Neuroendocrine Carcinoma With a Treatment Emergent Novel KANK1-ALK Fusion

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00230 JCO Precision Oncology no. 7 (2023) e2200230. Published online January 9, 2023. PMID: 36623237 Rapid and Deep Response to Lorlatinib in Pancreatic High-Grade Neuroendocrine Carcinoma With a Treatment Emergent Novel KANK1-ALK Fusion Farshid Dayyani , MD, PhD1xFarshid DayyaniSearch for articles by this author; Whayoung Lee , MD2xWhayoung LeeSearch for articles by this author; Roozbeh Houshyar , MD3xRoozbeh HoushyarSearch for articles by this author; and Pauline Fontaine, PharmD, PhD4xPauline FontaineSearch for articles by this author Show More 1Division of Hematology and Oncology, Department of Medicine, University of California, Orange, CA2Department of Pathology and Laboratory Medicine, University of California, Orange, CA3Department of Radiological Sciences, University of California, Orange, CA4Guardant Health Inc, Redwood City, CA https://doi.org/10.1200/PO.22.00230 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: Farshid DayyaniProvision of study materials or patients: Pauline FontaineCollection and assembly of data: Farshid Dayyani, Roozbeh Houshyar, Pauline FontaineData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Farshid DayyaniEmployment: Roche (I)Consulting or Advisory Role: Genentech/Roche, Array BioPharma, Exelixis, Eisai, QED Therapeutics, SignateraSpeakers' Bureau: Genentech/Roche, Amgen, Eisai, Ipsen, Exelixis, Sirtex Medical, Deciphera, Natera, ServierResearch Funding: Bristol Myers Squibb (Inst), AstraZeneca (Inst), Merck (Inst), Genentech (Inst), Taiho Pharmaceutical (Inst), Exelixis (Inst), Ipsen (Inst)Pauline FontaineEmployment: Guardant HealthStock and Other Ownership Interests: Guardant HealthHonoraria: Guardant HealthTravel, Accommodations, Expenses: Guardant HealthNo other potential conflicts of interest were reported.